Eugeen Vanmechelen

List of Publications by Year in Descending Order

117 papers	10,344 citations	54 h-index	101 g-index
126 ext. papers	11,816 ext. citations	5 avg, IF	5.46 L-index

#	Paper	IF	Citations
117	Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.. *Annals of Neurology*, **2022**,	9.4	3
116	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease.. *EBioMedicine*, **2022**, 76, 103836	8.8	4
115	Comparing tau status determined via plasma pTau181, pTau231 and [F]MK6240 tau-PET.. *EBioMedicine*, **2022**, 76, 103837	8.8	1
114	Cerebrospinal fluid neurogranin in Alzheimer's disease studies: are immunoassay results interchangeable?. *Clinical Chemistry and Laboratory Medicine*, **2022**, 60, e13-e17	5.9	
113	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.. *Alzheimer's Research and Therapy*, **2022**, 14, 65	9	2
112	Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer's disease.. *Annals of Clinical and Translational Neurology*, **2022**,	5.3	2
111	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. *Alzheimer's Research and Therapy*, **2021**, 13, 198	9	14
110	The β-secretase BACE1 in Alzheimer's Disease. *Biological Psychiatry*, **2021**, 89, 745-756	7.9	107
109	Plasma β-secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. *Alzheimer's and Dementia*, **2021**, 17, 629-640	1.2	4
108	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathologica*, **2021**, 141, 709-724	14.3	83
107	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. *Neurology*, **2021**, 97, e1681-e1694	6.5	10
106	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. *Alzheimer's and Dementia*, **2021**,	1.2	11
105	Exploring molecular biomarkers with potential prognostic value in longitudinal observational studies on Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e047017	1.2	
104	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. *Frontiers in Molecular Biosciences*, **2020**, 7, 48	5.6	0
103	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. *Neurobiology of Aging*, **2020**, 88, 83-90	5.6	3
102	β-secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. *Alzheimer's Research and Therapy*, **2020**, 12, 130	9	2
101	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2020**, 12, 88	9	6

100	BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients. *Journal of Alzheimers Disease*, **2020**, 77, 313-322	4.3	3
99	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A pathology are detected. *EMBO Molecular Medicine*, **2020**, 12, e12921	12	67
98	Plasma amyloid 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. *Alzheimers and Dementia*, **2019**, 15, 764-775	1.2	86
97	The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. *Acta Neuropathologica Communications*, **2019**, 7, 31	7.3	35
96	Pre-analytical stability of novel cerebrospinal fluid biomarkers. *Clinica Chimica Acta*, **2019**, 497, 204-211	6.2	8
95	Brain A load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. *Alzheimers and Dementia*, **2019**, 15, 1274-1285	1.2	9
94	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. *Alzheimers and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 871-882	6	45
93	Critical Steps to be Taken into Consideration Before Quantification of Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. *Neurology and Therapy*, **2019**, 8, 129-145	4.6	6
92	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. *Clinical Chemistry*, **2018**, 64, 927-937	5.5	27
91	Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples. *Analytica Chimica Acta*, **2018**, 1015, 74-81	6.6	37
90	Relevance of A 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM Scale. *Frontiers in Aging Neuroscience*, **2018**, 10, 138	5.3	32
89	P1-251: CSF-NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER'S DISEASE SPECIFIC BIOMARKER **2018**, 14, P376-P376		
88	Cerebrospinal fluid neurogranin/ site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. *Alzheimers and Dementia: Translational Research and Clinical Interventions*, **2018**, 4, 617-627	6	17
87	Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study. *Dementia and Geriatric Cognitive Disorders Extra*, **2018**, 8, 277-289	2.5	16
86	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. *BMC Neurology*, **2017**, 17, 170	3.1	44
85	The utility of synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. *Biomarkers in Medicine*, **2016**, 10, 19-34	2.3	67
84	Association of Plasma A 40 Peptides, But Not A 42, with Coronary Artery Disease and Diabetes Mellitus. *Journal of Alzheimers Disease*, **2016**, 52, 161-9	4.3	10
83	Validation of soluble amyloid- precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. *Journal of Neurochemistry*, **2016**, 137, 112-21	6	15

82	Assessing the commutability of reference material formats for the harmonization of amyloid- measurements. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1177-91	5.9	48
81	A First Tetraplex Assay for the Simultaneous Quantification of Total Synuclein, Tau, Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. *PLoS ONE*, **2016**, 11, e0153564	3.7	6
80	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. *Journal of Alzheimers Disease*, **2016**, 53, 1523-38	4.3	40
79	Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. *Journal of Biological Chemistry*, **2015**, 290, 4059-74	5.4	16
78	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. *Neurobiology of Aging*, **2015**, 36, 2587-96	5.6	29
77	TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. *Acta Neuropathologica Communications*, **2015**, 3, 15	7.3	29
76	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. *Alzheimers and Dementia*, **2015**, 11, 1461-1469	1.2	95
75	P4-232: A monoclonal antibody-based elisa for neurogranin **2015**, 11, P869-P869		1
74	A Practical Guide to Immunoassay Method Validation. *Frontiers in Neurology*, **2015**, 6, 179	4.1	223
73	Increased CSF Synuclein levels in Alzheimer's disease: correlation with tau levels. *Alzheimers and Dementia*, **2014**, 10, S290-8	1.2	54
72	P2-127: TDP-43 AS A BIOMARKER FOR FRONTOTEMPORAL LOBE DEGENERATION: A SYSTEMATIC REVIEW OF EXISTING ANTIBODIES **2014**, 10, P517-P518		
71	Monitoring of amyloid dynamics after human traumatic brain injury. *Journal of Neurotrauma*, **2014**, 31, 42-55	5.4	47
70	Functional mannose-binding lectin haplotype variants are associated with Alzheimer's disease. *Journal of Alzheimers Disease*, **2013**, 35, 121-7	4.3	10
69	Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. *Journal of Alzheimers Disease*, **2013**, 33, 117-31	4.3	34
68	Evaluation of plasma A as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. *Journal of Alzheimers Disease*, **2012**, 28, 231-8	4.3	37
67	Potential sources of interference on Abeta immunoassays in biological samples. *Alzheimers Research and Therapy*, **2012**, 4, 39	9	10
66	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. *Biomarkers in Medicine*, **2012**, 6, 419-30	2.3	230
65	Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. *Archives of Neurology*, **2012**, 69, 1445-52		327

64	Analytical aspects of molecular Alzheimer's disease biomarkers. *Biomarkers in Medicine*, **2012**, 6, 377-89	2.3	24
63	Identification of novel □synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. *Neurochemical Research*, **2011**, 36, 2029-42	4.6	74
62	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. *Archives of Neurology*, **2010**, 67, 949-56		344
61	Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. *Neurobiology of Aging*, **2010**, 31, 357-67	5.6	197
60	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. *Neurobiology of Aging* , **2010**, 31, 1867-76	5.6	53
59	Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. *Journal of Alzheimer's Disease*, **2010**, 21, 1119-28	4.3	94
58	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. *Brain Research*, **2010**, 1362, 13-22	3.7	156
57	Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. *Journal of Nutrition, Health and Aging*, **2009**, 13, 205-8	5.2	37
56	Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?. *Neuroscience Letters*, **2009**, 450, 332-5	3.3	175
55	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. *Neurobiology of Aging*, **2008**, 29, 812-8	5.6	84
54	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. *Neurobiology of Aging*, **2008**, 29, 1143-59	5.6	181
53	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. *Expert Review of Proteomics*, **2008**, 5, 207-24	4.2	197
52	Characterization of tau in cerebrospinal fluid using mass spectrometry. *Journal of Proteome Research*, **2008**, 7, 2114-20	5.6	62
51	Tau as a biomarker of neurodegenerative diseases. *Biomarkers in Medicine*, **2008**, 2, 363-84	2.3	61
50	Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. *Journal of Alzheimer's Disease*, **2007**, 12, 255-60	4.3	105
49	No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. *Brain*, **2007**, 130, 2320-6	11.2	95
48	Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. *Clinical Chemistry and Laboratory Medicine*, **2006**, 44, 1472-80	5.9	100
47	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. *Neuropathology and Applied Neurobiology*, **2006**, 32, 318-31	5.2	19

46	Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. *Clinical Chemistry*, **2005**, 51, 336-45	5.5	358
45	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. *Neurobiology of Disease*, **2005**, 20, 625-37	7.5	65
44	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. *Annals of Neurology*, **2005**, 58, 748-57	9.4	119
43	Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. *Clinical Chemistry*, **2005**, 51, 1650-60	5.5	73
42	The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2005**, 19, 256-65	2.6	65
41	Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. *Archives of General Psychiatry*, **2004**, 61, 95-102		336
40	Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. *NeuroToxicology*, **2004**, 25, 471-80	4.4	16
39	Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. *Archives of Neurology*, **2004**, 61, 333-7		94
38	Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. *Dementia and Geriatric Cognitive Disorders*, **2003**, 15, 169-76	2.6	138
37	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. *Journal of Neuroscience Research*, **2003**, 72, 520-6	4.4	47
36	Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. *Acta Neurologica Scandinavica*, **2003** , 179, 47-51	3.8	107
35	Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. *Journal of Neurochemistry*, **2003**, 85, 1581-91	6	176
34	Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. *Molecular Psychiatry*, **2003**, 8, 343-7	15.1	182
33	Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets. *Dementia and Geriatric Cognitive Disorders*, **2003**, 16, 93-7	2.6	12
32	CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. *Brain Research Bulletin*, **2003**, 61, 235-42	3.9	60
31	Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. *Dementia and Geriatric Cognitive Disorders*, **2002**, 13, 112-8	2.6	110
30	Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease. *Neurobiology of Aging*, **2002**, 23, 205-11	5.6	20
29	The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. *Dementia and Geriatric Cognitive Disorders*, **2001**, 12, 257-64	2.6	81

28	CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. *Molecular Neurobiology*, **2001**, 24, 87-97	6.2	186
27	Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. *Mechanisms of Ageing and Development*, **2001**, 122, 2005-11	5.6	39
26	Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. *Archives of Neurology*, **2001**, 58, 373-9		372
25	An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. *Neurochemistry International*, **2001**, 38, 557-65	4.4	68
24	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. *Neuroscience Letters*, **2001**, 297, 187-90	3.3	347
23	Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. *Neuroscience Letters*, **2001**, 314, 33-6	3.3	64
22	Tau and A□42 in Cerebrospinal Fluid from Healthy Adults 21□93 Years of Age: Establishment of Reference Values. *Clinical Chemistry*, **2001**, 47, 1776-1781	5.5	351
21	Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/ionization--mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry. *Electrophoresis*, **2000**, 21, 2266-83	3.6	84
20	Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. *Leukemia*, **2000**, 14, 2076-84	10.7	23
19	CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. *Journal of Neural Transmission*, **2000**, 107, 563-79	4.3	194
18	Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. *Journal of Alzheimer's Disease*, **2000**, 2, 199-206	4.3	160
17	Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. *Neuroscience Letters*, **2000**, 284, 85-8	3.3	70
16	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. *Neuroscience Letters*, **2000**, 285, 49-52	3.3	397
15	Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. *Human Molecular Genetics*, **2000**, 9, 2589-98	5.6	112
14	Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2000**, 7, 245-58	2.7	268
13	Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. *Archives of Neurology*, **1999**, 56, 673-80		518
12	Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. *Dementia and Geriatric Cognitive Disorders*, **1999**, 10, 442-5	2.6	25
11	Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion. *Human Molecular Genetics*, **1999**, 8, 1529-40	5.6	74

10	The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease. *American Journal of Human Genetics*, **1999**, 64, 290-2	11	43
9	Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. *Neurobiology of Disease*, **1999**, 6, 280-7	7.5	48
8	Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. *Neuroscience Letters*, **1999**, 273, 5-8	3.3	205
7	Postmortem changes in the phosphorylation state of tau-protein in the rat brain. *Neurobiology of Aging*, **1998**, 19, 535-43	5.6	49
6	Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation. *Neuroscience Letters*, **1996**, 220, 9-12	3.3	31
5	Developmental expression of tau proteins in the chicken and rat brain: rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. *International Journal of Developmental Neuroscience*, **1995**, 13, 607-17	2.7	27
4	Generation and characterization of mouse microglial cell lines. *Journal of Neuroimmunology*, **1994**, 52, 153-64	3.5	33
3	Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. *Journal of Neurochemistry*, **1993**, 61, 1828-34	6	423
2	CSF Markers for Early Alzheimer's Disease275-283		
1	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer□ disease		2